The present invention provides a novel synergistic pharmaceutical co-crystal of Mesalamine or its pharmaceutically acceptable salts as API along with coformers such as alpha amino acids, flavones or nutraceuticals for the treatment of inflammatory bowel disease, Crohn"s disease, ulcerative colitis, indeterminate colitis.